- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 40FR12B Initial registration of securities (Canada)
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 99.12 Exhibit 99.12
- 99.13 Exhibit 99.13
- 99.14 Exhibit 99.14
- 99.15 Exhibit 99.15
- 99.16 Exhibit 99.16
- 99.17 Exhibit 99.17
- 99.18 Exhibit 99.18
- 99.19 Exhibit 99.19
- 99.20 Exhibit 99.20
- 99.21 Exhibit 99.21
- 99.22 Exhibit 99.22
- 99.23 Exhibit 99.23
- 99.24 Exhibit 99.24
- 99.25 Exhibit 99.25
- 99.26 Exhibit 99.26
- 99.27 Exhibit 99.27
- 99.28 Exhibit 99.28
- 99.29 Exhibit 99.29
- 99.30 Exhibit 99.30
- 99.31 Exhibit 99.31
- 99.32 Exhibit 99.32
- 99.33 Exhibit 99.33
- 99.34 Exhibit 99.34
- 99.35 Exhibit 99.35
- 99.36 Exhibit 99.36
- 99.37 Exhibit 99.37
- 99.38 Exhibit 99.38
- 99.39 Exhibit 99.39
- 99.40 Exhibit 99.40
- 99.41 Exhibit 99.41
- 99.42 Exhibit 99.42
- 99.43 Exhibit 99.43
- 99.44 Exhibit 99.44
- 99.45 Exhibit 99.45
- 99.46 Exhibit 99.46
- 99.47 Exhibit 99.47
- 99.48 Exhibit 99.48
- 99.49 Exhibit 99.49
- 99.50 Exhibit 99.50
- 99.51 Exhibit 99.51
- 99.52 Exhibit 99.52
- 99.53 Exhibit 99.53
- 99.54 Exhibit 99.54
- 99.55 Exhibit 99.55
- 99.56 Exhibit 99.56
- 99.57 Exhibit 99.57
- 99.58 Exhibit 99.58
- 99.59 Exhibit 99.59
- 99.60 Exhibit 99.60
- 99.61 Exhibit 99.61
- 99.62 Exhibit 99.62
- 99.63 Exhibit 99.63
- 99.64 Exhibit 99.64
- 99.65 Exhibit 99.65
- 99.66 Exhibit 99.66
- 99.67 Exhibit 99.67
- 99.68 Exhibit 99.68
- 99.69 Exhibit 99.69
- 99.70 Exhibit 99.70
- 99.71 Exhibit 99.71
- 99.72 Exhibit 99.72
- 99.73 Exhibit 99.73
- 99.74 Exhibit 99.74
- 99.75 Exhibit 99.75
- 99.76 Exhibit 99.76
- 99.77 Exhibit 99.77
- 99.78 Exhibit 99.78
- 99.79 Exhibit 99.79
- 99.80 Exhibit 99.80
- 99.81 Exhibit 99.81
- 99.82 Exhibit 99.82
- 99.83 Exhibit 99.83
- 99.84 Exhibit 99.84
- 99.85 Exhibit 99.85
- 99.86 Exhibit 99.86
- 99.87 Exhibit 99.87
- 99.88 Exhibit 99.88
- 99.89 Exhibit 99.89
- 99.90 Exhibit 99.90
- 99.91 Exhibit 99.91
- 99.92 Exhibit 99.92
- 99.93 Exhibit 99.93
- 99.94 Exhibit 99.94
- 99.95 Exhibit 99.95
- 99.96 Exhibit 99.96
- 99.97 Exhibit 99.97
- 99.98 Exhibit 99.98
- 99.99 Exhibit 99.99
- 99.100 Exhibit 99.100
- 99.101 Exhibit 99.101
- 99.102 Exhibit 99.102
- 99.103 Exhibit 99.103
- 99.104 Exhibit 99.104
- 99.105 Exhibit 99.105
- 99.106 Exhibit 99.106
- 99.107 Exhibit 99.107
- 99.108 Exhibit 99.108
- 99.109 Exhibit 99.109
- 99.110 Exhibit 99.110
- 99.111 Exhibit 99.111
- 99.112 Exhibit 99.112
- 99.113 Exhibit 99.113
- 99.114 Exhibit 99.114
- 99.115 Exhibit 99.115
- 99.116 Exhibit 99.116
- 99.117 Exhibit 99.117
- 99.118 Exhibit 99.118
- 99.119 Exhibit 99.119
- 99.120 Exhibit 99.120
- 99.121 Exhibit 99.121
- 99.122 Exhibit 99.122
- 99.123 Exhibit 99.123
- 99.124 Exhibit 99.124
- 99.125 Exhibit 99.125
- 99.126 Exhibit 99.126
- 99.127 Exhibit 99.127
- 99.128 Exhibit 99.128
- 99.129 Exhibit 99.129
- 99.130 Exhibit 99.130
- 99.131 Exhibit 99.131
- 99.132 Exhibit 99.132
- 99.133 Exhibit 99.133
- 99.134 Exhibit 99.134
- 99.135 Exhibit 99.135
- 99.136 Exhibit 99.136
- 99.137 Exhibit 99.137
- 99.138 Exhibit 99.138
- 99.139 Exhibit 99.139
- 99.140 Exhibit 99.140
- 99.141 Exhibit 99.141
- 99.142 Exhibit 99.142
- 99.143 Exhibit 99.143
- 99.144 Exhibit 99.144
- 99.145 Exhibit 99.145
- 99.146 Exhibit 99.146
- 99.147 Exhibit 99.147
- 99.148 Exhibit 99.148
- 99.149 Exhibit 99.149
- 99.150 Exhibit 99.150
- 99.151 Exhibit 99.151
- 99.152 Exhibit 99.152
- 99.153 Exhibit 99.153
- 99.154 Exhibit 99.154
- 99.155 Exhibit 99.155
- 99.156 Exhibit 99.156
- 99.157 Exhibit 99.157
- 99.158 Exhibit 99.158
- 99.159 Exhibit 99.159
- 99.160 Exhibit 99.160
- 99.161 Exhibit 99.161
- 99.162 Exhibit 99.162
- 99.163 Exhibit 99.163
- 99.164 Exhibit 99.164
- 99.165 Exhibit 99.165
- 99.166 Exhibit 99.166
- 99.167 Exhibit 99.167
- 99.168 Exhibit 99.168
- 99.169 Exhibit 99.169
- 99.170 Exhibit 99.170
- 99.171 Exhibit 99.171
- 99.172 Exhibit 99.172
- 99.173 Exhibit 99.173
- 99.174 Exhibit 99.174
Form 51-102F3
Material Change Report
Item 1 | Name and Address of Company |
| ZEN Graphene Solutions Ltd. (the "Company") |
| 210 - 1205 Amber Drive |
| Thunder Bay, ON P7B 6M4 |
Item 2 | Date of Material Change |
| January 18 2021 |
Item 3 | News Release |
| The news release was disseminated on January 18 2021 |
Item 4 | Summary of Material Change |
Item 5 | Full Description of Material Change |
Item 6 | Reliance on subsection 7.1(2) of National Instrument 51-102 |
| Neither subsection 7.1(2) nor (3) of National Instrument 51-102 is being relied upon. |
Item 7 | Omitted Information |
| No information has been omitted on the basis that it is confidential information. |
Item 8 | Executive Officer |
| Francis Dubé |
| Executive Chairman |
| Tel: +1 (844) -730-9822 |
| Cell: +1 (289) 821-2820 |
| Email: drfdube@zengraphene.com |
DATED: | January 18 2021 |
- 2 -
Schedule "A"
ZEN Graphene Solutions and TreborRx Announce
Nitrile Glove Agreement and Provide Health Canada Update
Guelph, ON - January 18, 2021, ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSX-V:ZEN and OTC:ZENYF) is pleased to announce the following related to its proprietary, graphene-based coating that is 99.9% effective against aerobic bacteria (gram-positive and gram-negative), fungi and viruses, including COVID-19:
• On January 16th, 2021, ZEN reached an agreement with TreborRx (Trebor) for application of its coating on nitrile gloves sourced or produced by Trebor
• ZEN will provide Trebor with a distribution agreement for Canada, the USA and Mexico (Territory)
• Trebor agrees to use the coating on all gloves sold and will pay ZEN a royalty per glove coated, with a minimum first year guarantee of 100 million gloves
• Trebor surgical masks without our coating have received Health Canada (HC) approval as a level 1 medical device in line with American Society for Testing and Materials (ASTM) standards, and expect HC approval for level 2 and 3 shortly
Greg Fenton, ZEN CEO, commented: "We are very excited to build upon our initial partnership agreement with the team at TreborRx by extending the benefits of our coating to the nitrile glove market. This is a tremendous opportunity for both our companies and demonstrates the strength of our relationship and mutual pursuit of creating value and protecting our front-line workers. Additionally, we are pleased that both companies continue to make progress toward getting Health Canada approval and bringing PPE treated with our biocidal coating to market."
George Irwin, Trebor CEO, commented: " We are excited to bring another game changer to the PPE Industry. We believe Zen's biocidal coating on gloves gives front line respoders and health care associates in all medical and non-medical situations additional protection for both the patient and health care worker. This coating can be used on gloves in food processing and agriculture as well. Trebor and Zen have a unique relationship with the goal of making safer PPE. Trebor looks forward to suppling the biocidal gloves within the 1st half of 2021.
- 3 -
Mask and Filter Agreement Update
With Trebor having received HC approval for their ASTM level 1 surgical mask and expecting level 2 and 3 shortly, ZEN is currently carrying out testing in accordance with ISO 10993-10 (Tests for Irritation and Skin Sensitization) and ISO 10993-5 (Tests for In Vitro Cytotoxicity) as this data is necessary for Trebor to apply for an amendment to HC to include our coating on their masks. ZEN will provide updates on this process in due course. A submission to HC will immediately follow successful completion of all testing.
Concurrently, ZEN has hired Bantrel, an engineering company to design and source the equipment for the production of our proprietary formula at industrial scale. The equipment will be assembled and installed in our new industrial facility in Guelph, Ontario. This work is ongoing and the company will report on progress as the project advances.
Disclaimer: The Company is not making any express or implied claims that its product can eliminate, cure, or contain the COVID-19 virus (or SARS-2 Coronavirus) at this time
About ZEN Graphene Solutions Ltd.
ZEN is a graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN's Albany PureTM Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods. ZEN is focused on commercializing a patent pending graphene-based coating with 99% viricidal activity against COVID-19.
For further information:
Greg Fenton, Chief Executive Officer
Tel: +1 (437) 220-8140
Email: gfenton@zengraphene.com
To find out more about ZEN Graphene Solutions Ltd., please visit our website at www.ZENGraphene.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.ca.
- 4 -
About Trebor Rx Corp.
Trebor Rx Corp. is led by George Irwin and Brenda Elliott, the 3rd generation Canadian business icons behind the Irwin Toy brand, which has been operating in Canada almost 100 years. Fueled by a dedicated and compassionate team prioritizing safety and innovation, Trebor is disrupting the PPE industry and setting a new standard of production for masks face shields and nitrile gloves while solving problems of cost, comfort and medical waste. A proudly Canadian company with a production facility located in Collingwood, Ontario, Trebor is committed to providing Healthcare, Frontline and Essential workers with innovative, new patented technology PPE during COVID-19 and beyond.
For Further information:
George Irwin CEO Trebor Rx Corp.
Tel: +1-416-625-7499
George.irwin@treborrx.com
Forward-Looking Statements
This news release contains forward-looking statements. Since forward- looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although ZEN believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. ZEN disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.